Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
OPIOID DELIVERY SYSTEM
Field of the invention
This invention relates to pharmaceutical preparations and methods of
administering same and, more particularly, to opioid based analgesics and a
method for
their administration.
Background of the invention
Opioids are among the oldest drugs in existence, and remain a mainstay of pain
management. Opium, the original opioid, is derived from poppy plants.
"Opiates" are
natural derivatives of opium, and include morphine, methadone, and heroin.
"Opioids"
are a broader class of drugs, that includes opium, opiates, and synthetic
drugs with the
same pharmacological effect of opium. Commonly used synthetic opioids include
meperidine, fentanyl, alfentanil, sufentanil, and remifentanil.
Opioids are believed to exert their effects through binding of the mu receptor
in
the spinal cord and brain, and peripheral tissues. Binding at the mu receptor
induces a
wide variety of pharmacological effects, including therapeutic effects such as
analgesia,
effects which may be viewed as either side effects or therapeutic effects,
depending on
context, including sedation and decreased bowel motility, side effects such as
nausea,
vomiting, urinary retention, pruritis, ventilatory depression, addiction, and
toxicity such
as severe ventilatory depression, loss of consciousness and death.
Opioids differ from each other in many ways, including their route of
delivery,
their physicochemical composition, their drug absorption rate, their
pharmacolcinetics,
and their pharmacodynamics. Noninvasive routes of opioid delivery include
oral, rectal,
transdermal, transmucosal, and via inhalation. Invasive routes of opioid
delivery include
intravenous, intramuscular, epidural, spinal, and by injection into joints.
When injected
intravenously, some opioids quickly enter the brain and spinal cord and thus
have a very
rapid onset of drug effect (e.g., alfentanil and remifentanil), while others
are absorbed
slowly to the site of action and have very slow onset of drug effect (e.g.,
morphine).
Similarly, for some opioids the drug effect is very short-lived, owing to very
rapid
metabolism (e.g., remifentanil), while other opioids may have very slow
metabolism and
prolonged effect (e.g., methadone). In terms of pharmacodynamics, the potency
of
opioids covers nearly 5 orders of magnitude, from extraordinarily potent
opioids such as
1
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
carfentanil and etorphine (both used to stun elephants) to relatively less
potent drugs such
as methadone and morphine. The equivalent potencies of opioids (measured as a
"therapeutic equivalence ratio") are well established in the literature, and
are often used
when changing a patient's treatment regimen from one opioid to another.
Despite these differences, all opioids have the same potential to produce both
profound levels of analgesia, and profound toxicity from hypoxia, which can be
fatal.
Because of the risk of hypoxia, physicians are reluctant to use appropriate
doses of
opioids to treat acute and chronic pain. As a result, hundreds of thousands of
patients who
could be provided better pain control receive inadequate doses of opioids.
Conversely,
even with an understandably cautious approach by the health care community to
treatment of pain, every year, many patients die from opioid-induced
ventilatory
depression.
Pain is highly variable and highly subjective. Different patients respond
differently to opioids. As a result, different patients need different amounts
of analgesia
to treat their pain. As such, it has become desirable to allow patients to
vary the amount
of analgesic they receive.
One attempt to better adjust opioid dosing in patients has been the
introduction of
"patient controlled analgesia" ("PCA") (Ballantyne JC, et al. Postoperative
patient-
controlled analgesia: Meta-analyses of initial randomized control trials. .I
Clin Afz.esth
1993:5:182-193.) With the PCA system, the patient must be awake, and must
activate a
delivery mechanism to receive more opioid, before the drug is given. If the
patient
becomes overdosed from the opioid, then the patient will become unconscious
and not
request additional drug. In this manner, the PCA system uses a side effect of
opioid,
sedation, to limit the amount of opioid given. One problem with the PCA system
is that
the drug is injected rapidly after the patient requests it (typically, the
time frame of
administration of drug is under 1 minute) and because the drug most frequently
used in
the PCA is morphine, a drug that is slowly transferred from the plasma to the
site of
action - this results in a delay between the patient request for drug and the
analgesic effect
of the drug. As a result of this delay, patients often request a second (or
third) dose of the
drug while the opioid effect level of the first injection is still rising. PCA
systems include
a "lockout" period (commonly 5 minutes), which helps prevent patients from
administering more opioid while the opioid drug effect is still rising.
Lockout periods are
2
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
typically controlled, defined or programmed by the health care provider, and
there have
been many instances where user error or inadvertence in programming the
lockout period
have resulted in the death of the patient. The patient also often feels
frustrated by the
lockout, as it diminishes the patients' control of dosing. Other disadvantages
of the PCA
include the invasive parenteral (intravenous) administration as well as the
expensive
infusion pumps thus restricting the use of the PCA to institutionalized
patients.
A second attempt to better adjust opioid dosing in patients is in the self
administration of Nitrous Oxide during labour associated with childbirth. A
nitrous oxide
mask is held to the face by the patient during contractions, and is released
from the face
when adequate analgesia is achieved. However, tlus mechanism is a titration to
analgesic
effect and not used as a safety mechanism, since overdosing on nitrous oxide
using this
system of administration is not a significant concern. Furthermore, nitrous
oxide is a gas
which requires a heavy steel tank for storage and a complex delivery system
for
administration. Therefore, the use of nitrous oxide is primarily restricted to
the hospital
environment and not for ambulatory patients. An additional potential problem
with
nitrous oxide relates to its low potency and thus the necessity of
administering a high
concentration (more than 50%) of nitrous oxide in oxygen with a potential of a
hypoxic
mixture.
The current invention seeks to use two physiological responses of opioids:
sedation and ventilatory depression, to limit the total dose of opioids that
patients receive.
In this mamler, the invention seeks to increase safety of opioid drug delivery
beyond what
is currently accomplished with PCA or other existing opioid administration
methods
whereby only a single side effect is used to limit the exposure of patients to
dangerously
high levels of opioid drug effects. The invention also improves the use of
sedation by
removing the need for a "lockout" period, currently required in PCA systems,
and
removing the frustration and user error possible therein.
Summary of the invention
Accordingly, the invention provides in accordance with a first aspect, an
opioid
formulation for use in a method of providing analgesia to a patient comprising
the steps
of
3
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
continuously inhaling the formulation using a pulmonary drug delivery device
to
produce analgesia; and
stopping inhalation when satisfactory analgesia is achieved or at the onset of
a
side effect;
wherein the formulation comprises an effective amount of at least one rapid-
onset
opioid; and a pharmaceutically acceptable carrier, the concentration and type
of each
opioid, and amount of and particle size of the formulation delivered from the
device on
each inhalation, being selected so that, during inhalation, analgesia is
achieved before the
onset of said side effect, and the onset of said side effect occurs before the
onset of
toxicity, and so that the maximum total opioid plasma concentration does not
reach toxic
levels, whereby the onset of said side effect can be used by the patient to
terminate
inhalation to avoid toxicity.
The concentration of each opioid is such that the at least one opioid enters
the
patient's system in an incremental and gradual fashion so that analgesia is
achieved,
followed by the onset of side effects, and well in advance of toxicity. Any
conventional
diluent suitable for use in formulations for pulmonary administration may be
used such as
saline or sterile water. It will be appreciated that the concentration will be
adjusted based
on other parameters, including the type of pulmonary delivery device that is
used and,
more pauticularly, the amount of formulation which is dispensed by the device
on each
inhalation and particle size of the formulation dispensed (expressed in terms
of "mass
medium aerodynamic diameter").
In order that the formulation is bioavailable (i.e. is deposited in the
lungs), the
formulation should be dispensed by the pulmonary drug delivery device at a
mass
medium aerodynamic diameter of from 1 to 5 microns, or from 1 to 3 microns, or
from
1.5 to 2 microns.
To avoid toxicity following termination of inhalation, the maximum total
opioid
plasma concentration at the onset of side effect is preferably no less than
66% of the
maximum total opioid plasma concentration, and more preferably no less than
80% of the
maximum total opioid plasma concentration.
The rapid-onset opioid may be chosen from fentanyl, alfentanil, sufentanil and
remifentanil and is preferably fentanyl and alfentanil. When used as the sole
rapid-onset
4
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
opioid, the amount of sufentanil may range from 1.7 to 100 mcg/ml and' the
amount of
remifentanil may range from 3.3 to 3300 mcg/ml.
In order to reduce the frequency of administration, the opioid formulation may
comprise an effective amount of at least one sustained-effect opioid to
provide sustained
relief. It will be appreciated that the relative concentration of the
sustained-effect opioid
and rapid-onset opioid must be adjusted in order that the formulation may
still achieve the
same desired result, namely, to produce analgesia followed by at least one
side effect
before a toxic level of opioid in plasma is reached, and to avoid toxic levels
being reach
after termination of inhalation. In mixed formulations contained rapid-onset
and
sustained-effect opioids, the rapid-onset opioid serves to limit the dose of
both drugs
below a dose that would cause toxicity.
The sustained-effect opioid may be chosen from morphine, morphine-6-
glucuronide, methadone, hydromorphone, meperidine, an opioid encapsulated in a
biocompatible carrier that delays release of the drug at the lung surface (as
are l~nown in
the art), and a liposome encapsulated opioid (e.g.. liposomally encapsulated
fentanyl).
Morphine-6-glucuronide may be present in a concentration of from 3.3 to 3300
mg/ml,
methadone may be present in a concentration of from 0.3 to 33 mg/ml,
hydromorphone
may be present in a concentration of from 0.03 to 7 mg/ml, and meperidine may
be
present in a concentration of from 1.7 to 170 mg/ml.
I?epending on the identity of the opioids used in the formulation, the ratio
of
concentration of total sustained-effect opioid to concentration of total rapid-
onset opioid
will vary. A preferred formulation giving rise to both rapid-onset and
sustained analgesic
effect is one in which the opioids consist of fentanyl and liposomally
encapsulated
fentanyl. The ratio of concentration of liposomally encapsulated fentanyl to
fentanyl may
be from 1:2 to 6:1, or from 1:1 to 5:1, or from 2:1 to 4:1, or about 3:1.
Furthermore, the
total opioid concentration may be from 250 to 1500 mcg/ml.
The liposomally encapsulated fentanyl may be present in a concentration of
from
3.3 to 3300, or from 250 to 1500, or from 267 to 330, or from 100 to 750
mcg/ml. The
total opioid concentration may be about 500 mcg/ml, the fentanyl concentration
may be
about 200 mcg/ml and the liposomally encapsulated fentanyl concentration may
be about
300 mcg/ml.
5
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
The concentration of fentanyl, and amount and particle size of the formulation
delivered from the device, may be selected so that from 4 to 50, or from 10 to
20, or about
15 mcg/min., of ~entanyl is deposited in the lungs during inhalation.
The concentration of liposomally encapsulated fentanyl, and amount and
particle
size of the formulation delivered from the device, may be selected so that
from 5 to 150,
or from 10 to 90, or from 15 to 60, or from 20 to 45 mcg/min of liposomally
encapsulated
fentanyl is deposited in the lungs during inhalation.
In another embodiment, the opioids in the formulation may consist of
alfentanil
and morphine. The alfentanil may be present in a concentration of from 300 to
6700
mcg/ml. Furthermore, the concentration of alfentanil, and amount and particle
size of the
formulation delivered from the device, may be selected so that from 100 to
500, or about
250, mcg/min. of alfentanil is deposited in the lungs during inhalation. The
morphine
may be present in a concentration of from 650 to 13350 or from 0.3 to 33
mg/ml. As
well, the concentration of morphine, and amount and particle size of the
formulation
delivered from the device, may be selected so that from 100 to 2000, or from
200 to 1000,
or about 500, mcg/min of morphine is deposited in the lungs during inhalation.
In accordance with a second aspect of the invention, there is provided a
method of
administering an opioid formulation to provide analgesia to a patient,
comprising the
steps of:
continuously inhaling the formulation using a pulmonary drug delivery device
to
produce analgesia; and
stopping inhalation when satisfactory analgesia is achieved or at the onset of
a
side effect;
wherein the formulation comprises an effective amount of at least one rapid-
onset
opioid and a pharmaceutically acceptable carrier; the concentration and type
of each
opioid, and amount of and particle size of the formulation delivered from the
device on
each inhalation, being selected so that, during inhalation, analgesia is
achieved before the
onset of said side effect, and the onset of said side effect occurs before the
onset of
toxicity, and so that the maximum total opioid plasma concentration does not
reach toxic
levels, whereby the onset of said side effect can be used by the patient to
terminate
inhalation to avoid toxicity.
6
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
The pulmonary drug delivery device may comprise:
a container containing said formulation;
means for forming the formulation into particles having a mass medium
aerodynamic diameter of from 1 to 5 microns for delivery to a patient;
an outlet through which the formulation is dispensed; and
means for dispensing said formulation through said outlet;
wherein the device is adapted to dispense the formulation only through an
exercise
of conscious effort by the patient.
The time to onset of the side effect (e.g. ventilatory depression and/or
sedation)
will vary from patient to patient and will depend on factors such as the
opioids used, their
concentrations, relative amounts, and particle size. For example, the onset
may occur
from 3-15 minutes following the start of inhalation, and the side effect may
peals within
1-2 minutes after the patient stops inhaling the formulation (i.e. at the end
of dose).
Typically, the patient will inhale the formulation over a period of from about
2 to 20
minutes, at a normal inhalation rate, before the onset of side effects.
similarly, the time
after the end of the dose by which the maximum plasma concentration is reached
will also
vary based on various parameters include the above-mentioned parameters. For
example,
the maximum plasma concentration may be reached within 0 to 5 minutes
following the
end of dose. Normal inhalation rates are typically less than 20 and more often
from 5 to
15 breaths per minute.
In accordance with a third aspect of the invention, there is provided a
pulmonary
drug delivery device comprising:
a container containing a formulation comprising an effective amount of at
least
one rapid-onset opioid and a pharmaceutically acceptable carrier;
means for forming the formulation into particles having a mass medium
aerodynamic diameter of from 1 to 5 microns for delivery to a patient;
an outlet through which the formulation is dispensed; and
means for dispensing said formulation through said outlet;
7
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
wherein the device is adapted to dispense the formulation only through an
exercise
of conscious effort by the patient; and the concentration and type of each
opioid, and
amount of and particle size of the formulation delivered from the device on
each
inhalation, is selected so that, during inhalation, analgesia is achieved
before the onset of
said side effect, and the onset of said side effect occurs before the onset of
toxicity, and so
that the maximum total opioid plasma concentration does not reach toxic
levels, whereby
the onset of said side effect can be used by the patient to terminate
inhalation to avoid
toxicity. Examples of devices which require a conscious effort by the patient
to actuate
include those having a button which must be manually depressed using a certain
degree of
force, and those which are breath actuated.
The device may further comprise a mechanical or electrical delivery rate
controlling means for limiting the rate at which the formulation is dispensed
to below a
selected threshold such that the objects of the invention may be achieved. The
delivery
rate controlling means may include a mechanism for measuring ventilatory
depression
and limit the rate of dispensation based on this information. Ventilatory
depression may
be measured by the respiratory rate, inspiratory force or value of end tidal
CQ2 of the
patient.
The device may weigh from 250 to 2500 grams and may be designed such that the
weight is adjustable on a patient by patient basis. Furthermore, the outlet
may be
designed to be difficult to maintain in the patient's mouth if the patient is
not fully
conscious. For example, the outlet may comprise a fenestration which must be
sealed by
the lips of the patient in order for the formulation to be dispensed. In this
way, continued
administration of the formulation may be hampered by the onset of side effects
such as
sedation and ventilatory depression.
The invention also provides an opioid administration kit, in accordance with a
fourth aspect, comprising:
a pulmonary drug delivery device comprising a container; means for forming a
formulation contained in the container into particles having a mass medium
aerodynamic
diameter of from 1 to 5 microns for delivery to a patient; an outlet through
which the
formulation is dispensed; and means for dispensing said formulation through
said outlet;
wherein the device is adapted to dispense the formulation only through an
exercise of
conscious effort by the patient; and
8
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
an opioid formulation contained in the container or for receipt by the
container,
said formulation comprising an effective amount of at least one rapid-onset
opioid and a
pharmaceutically acceptable carrier; the concentration and type of each
opioid, and
amount of and particle size of the formulation delivered from the device on
each
inhalation, being selected so that, during inhalation, analgesia is achieved
before the onset
of said side effect, and the onset of said side effect occurs before the onset
of toxicity, and
so that the maximum total opioid plasma concentration does not reach toxic
levels,
whereby the onset of said side effect can be used by the patient to terminate
inhalation to
avoid toxicity; and
instructions for using said kit comprising the steps of continuously inhaling
the
formulation using a pulmonary drug delivery device to produce analgesia; and
stopping
inhalation when satisfactory analgesia is achieved or at the onset of a side
effect. The kit
might include an empty device which must be filled with the opioid formulation
prior to
administration. In such event, the instructions may include the step of pre-
filling the
container.
In accordance with further aspects of the invention, there is provided a use
of the
present formulation in providing analgesia to a patient and in the manufacture
of a
medicament for doing same.
Useful drug formulations and parameters for administration according to the
present invention can be determined by the person skilled in the art based on
known
pharmacological data as well as through pharmacokinetic and phannacodynamic
modeling as herein described. Such modeling is intended to ensure that
analgesic effect
is achieved before the onset of a side effect, and that the onset of the side
effect occurs
well in advance of toxicity, and to ensure that once the patient stops
inhaling the
formulation, there will not be a continued rise in total opioid concentration
in the plasma
to toxic levels.
Brief Description of the Drawings
Figure 1 is a flow diagram which represents a computer simulation model for
sedation.
Figure 2 is a flow diagram which represents a computer simulation model for
ventilatory depression.
9
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Figure 3 is a flow diagram which represents a computer simulation model for an
inhalation device.
Figure 4 is a flow diagram which represents a computer simulation model for
the
pharmacokinetic profiling of opioid as administered to a patient through a
pulmonary
route.
Figure 5 is a flow diagram which represents the StellaTM computer simulation
of
the pharmacokinetics of the administration of a single opioid.
Figure 6 is a graph showing output of the StellaTM computer simulation of
Figure
5 (ventilatory depression and sedation models disabled) expressed as a time
course of
quantity of opioid in the inhalation device and in the lung of the patient.
Figure 7 is a graph showing the time course of ventilatory depression in the
StellaTM computer simulation of Figure 5 (ventilatory depression and sedation
models
disabled).
Figure 8 is a graph showing the time course of quantity of opioid in the
inhalation
device and in the lung of the patient, in the StellaT~ computer simulation of
Figure 5
(ventilatory depression model enabled, sedation model disabled).
Figure 9 is a graph showing the time course of ventilatory depression in the
StellaTM computer simulation of Figure 5 (ventilatory depression model
enabled, sedation
model disabled).
Figure 10 is a graph showing the time course of quantity of opioid in the
inhalation device and in the lung of the patient, in the StellaTM computer
simulation of
Figure 5 (ventilatory depression and sedation models enabled).
Figure 11 is a graph showing the time course of ventilatory depression in the
StellaTM computer simulation of Figure 5 (ventilatory depression and sedation
models
enabled).
Figure 12 is a flow diagram which represents a computer simulation model for
the
administration of two opioids.
Figure 13 is a flow diagram which represents the StellaTM computer simulation
of
the pharmacokinetics of the administration of two opioids.
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Figure 14 is a graph showing the output of StellaTM computer simulation of
Figure
13 expressed as a time course of total quantity of opioid in the inhalation
device and in
the lung of the patient (ventilatory depression and sedation models enabled).
Figure 15 is a graph showing the time course of concentration of each opioid
and
of total opioid at the effect site in the StellaTM computer simulation of
Figure 13
(ventilatory depression and sedation models enabled).
Figure 16 is a graph showing the time course of ventilatory depression during
and
after delivery of opioids in the StellaTM computer simulation of Figure 13
(ventilatory
depression and sedation models enabled).
Figure 17 is a flow diagram which represents the StellaTM computer simulation
of
the pharmacokinetics of the administration of two opioids, where the two
opioids being
administered are alfentanil and morphine.
Figure 18 is a graph showing the time course of concentration of alfentanil,
morphine, and combined opioid at the effect site in the Stellar computer
simulation of
Figure 17 (ventilatory depression and sedation models enabled).
Figure 19 is a graph showing the time course of ventilatory depression in the
StellaTM computer simulation of Figure 17 (ventilatory depression and sedation
models
enabled).
Figure 20 is a graph showing maximum concentration of opioid in the plasma
against end of dose concentration of opioid in the plasma of patients
administered opioid.
Figure 20A shows patients administered with a combination of fentanyl and
liposomally
encapsulated fentanyl through a pulmonary route. Figure 20B shows patients
administered with fentanyl intravenously.
Figure 21 is a graph showing time to side/toxic effect versus time to end of
dose
for the side effects and toxic effects of patients administered a combination
of fentanyl
and liposomally encapsulated fentanyl through a pulmonary route.
Figure 22 is a table showing the statistical correlation of side effect to
toxic effect.
Detailed description of the invention
In this application, the following terms have the following meanings:
11
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
"Analgesic effect" or "analgesia" means the relief from pain resulting from
the
action of a drug.
"Drug delivery profile" means the concentration of the drug, over time, at the
site
of drug effect, as determined by the amount and rate of drug administered to
the patient
and the pharmacokinetics relating dose inhaled to concentration in the lungs,
plasma and
at the site of drug effect.
"Hypoxia" is a toxic effect of opioid administration, and is defined in this
application as a
decrease in blood 02 concentration to less than 90% saturation.
"Ventilatory depression" means a decrease in the rate, tidal volume, and/or
flow
rate of air into the lungs. Ventilatory depression may manifest as dizziness,
shortness of
breath, or a slowing in rate of breathing. "Opioid induced ventilatory
depression" refers
to ventilatory depression caused by the action of an opioid at a site of drug
effect.
"Sedation" means a decrease in attention, mental awareness, focus, and state
of
consciousness caused by opioids, and manifests in a lack of physical strength
(muscle
fatigue), lack of voluntary activity, lethargy, drowsiness, and sleep. "Opioid-
induced
sedation" refers to sedation caused by the action of an opioid at a site of
drug effect.
"Rapid onset", when used to describe a drug formulation, means a formulation
which has an analgesic effect that rapidly follows the rise in plasma opioid
concentration.
A "rapid onset opioid" is an opioid that has an analgesic effect within 5
minutes of
administration.
"Sustained effect" means a formulation which has an analgesic effect that is
sustained over several hours. A "sustained effect opioid" means an opioid that
has
analgesic effect that lasts over 2 hours.
"Side effect" means an effect of an opioid that is not analgesic or toxic. For
example, severe ventilatory depression is an example of opioid toxicity, while
mild
ventilatory depression and sedation are not considered signs of opioid
toxicity, but are
side effects of the opioid.
"Site of effect" refers to a physical or hypothetical site of drug action
within the
patient. "Site of effect" may be a compartment of the body, such as the brain,
the liver, or
the spleen, or it may be a theoretical and unknown location based on
correlation and
pharmacokinetic modeling. For example, it is known that opioids exert their
analgesic
12
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
actions, in part, in the substantia gelatinosa of the spinal cord, so this is
a site of opioid
analgesic effect. The concentration of opioid at the effect site may be
determined by
direct measurement, or through the use of pharmacolcinetic and pharmacodynamic
modeling.
"Effective amount" means the amount of drug needed to reach an analgesic
effect.
"mass medium aerodynamic diameter" means the aerodynamic diameter an
aerosol such that half of the cumulative mass of all particles is contained in
particles with
smaller (or larger) diameters and wherein the aerodynamic diameter is defined
as the
diameter of a unit-density sphere having the same gravitational settling
velocity as the
particle being measured.
"breathing rate" means the number of breaths taken per unit of time.
"Titration to effect" means administering an opioid until a satisfactory
analgesic
effect is felt by the patient, then ceasing achninistration of the opioid.
"Titration to side effect" means administering an opioid until a side effect
is felt,
then ceasing administration. The ceasing of administration may be voluntary
(for
example, by instructing patients to cease administration of the opioid when
they start to
feel drowsy, dizzy or short of breath) or involuntary (for example, when
patients are no
longer able to breathe effective dosages of opioid due to ventilatory
depression or
sedation).
The terms "toxic", "toxicity", "toxic effect" and "opioid toxicity" refer to
effects
of opioids that place a patient at risk of death. For example, opioids
commonly produce
modest amounts of ventilatory depression that pose little rislc to a patient.
This is not
considered an example of opioid toxicity. However, severe ventilatory
depression poses
the risk of hypoxia, loss of consciousness, and death. Thus, severe
ventilatory depression
is an example of opioid toxicity, while mild ventilatory depression is not
considered a
sign of opioid toxicity.
The present invention is for use in patient self administration of opioids.
The
invention utilizes the opioid's side effects to self regulate the amount of
opioid given to a
patient, thereby tailoring the dose to achieve the patient's analgesic
requirements, while
avoiding toxicity and death.
13
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
The use of the invention begins with the patient's perception of pain. There
are
many modalities of treating mild to moderate pain, but opioids are the
mainstay of
treatment for severe pain. In response to the severe pain, either the patient
or the patient's
care provider open a prefilled vial of opioid in liquid solution, or,
alternatively, in an
emulsion. The liquid is added to a nebulizer.
The nebulizer is then brought to the mouth, and is held there with the hand.
The
nebulizer is not attached to the face with straps, as this prevents the self
limiting
mechanism from working.
With each breath, the nebulizer releases a small amount of the liquid opioid
as an
aerosol. The aerosol passes through the patient's mouth and into the trachea
and lungs,
where the aerosolized opioid is deposited.
Throughout this patent application, the nebulizer is also called an inhaler or
an
aerosol pulmonary drug delivery device. An inhaler may refer to either a
nebulizer or a
nebulizer combined with a source of compressed air or oxygen, or any other
aerosol
generating device for the administration of drug by way of the lungs. An
aerosol
pulmonary drug delivery device refers to any device that allows the
aerosolization of a
substance for delivery into the lungs. Various nebulizer technologies are
lrnown and
available in the art.
The rate of onset of opioid drug effect is believed to be dictated by the
speed at
which the opioid enters the lungs and the rate at which the opioid crosses the
blood brain
barrier. Some opioids, such as alfentanil and remifentanil, cross the blood
brain barrier
very quickly, and thus produce very rapid onset of drug effect. Other opioids,
such as
morphine and morphine-6-glucuronide, cross the blood brain barrier very
slowly, and
thus produce a slow onset but sustained effect.
As the opioid crosses the blood brain barner, it starts to exert effects at
the site of
drug action. Although in some instances, patients may feel effects
differently, typically,
as concentration of opioid increases, the effects felt are analgesic effect,
side effect, and
toxic effect, in that order.
Ventilatory depression is up and down regulated by the opposing actions of
opioids (which depress ventilation) and carbon dioxide (which increases
ventilation). This
occurs in a feedback loop as follows: initially the opioids will depress
ventilation.
14
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Because the patient is not exhaling as much carbon dioxide, the level of
carbon dioxide in
the patient's blood will rise. As the carbon dioxide rises, it stimulates
ventilation, partly
offsetting the opioid-induced ventilatory depression. The opioid-induced
ventilatory
depression must come on sufficiently rapidly so that it occurs as the patient
is inhaling the
opioid, thus serving to limit the amount of opioid inhaled. However, it must
not come on
so rapidly as to place the patient at rislc of toxic effects before the carbon
dioxide has had
a chance to rise and offset the opioid induced ventilatory depression.
The amount of opioid inhaled by the patient each minute is proportional to the
ventilation during that minute. As ventilation becomes depressed, the rate of
opioid
delivery to the lungs is depressed proportionally. In this way, the rate of
delivery is
slowed by ventilatory depression, decreasing the ability of the patient to
self administer a
toxic dose of opioid. The slowed uptake of opioid from ventilatory depression
creates the
opportunity for complete cessation of drug delivery through the onset of
sedation.
As the opioids exert their analgesic effects, patients will become sedated, in
part
from the mitigation of their pain, in part due to the side effects of the
opioids. As sedation
develops in patients, it becomes difficult to hold the device to the mouth,
maintain a seal
with the lips, and breathe through the device to administer additional opioid.
Instead, the
patient begins to breathe through the nose, or through the mouth but around
the
mouthpiece of the nebulizer. With increasing sedation, the arm drops away from
the
airway, removing the device from the mouth. This dropping away of the arm may
be
encouraged to take place at a lower level of sedation by making the device
deliberately
heavy, or by adding a weight to the device. Weight of the device can be
adjusted from
patient to patient, depending on the individual patient's strength pre-
sedation.
Since the side effects of the opioids typically occur at lower opioid
concentrations
(as compared to the opioid toxic effects), a safer, patient self limited
opioid
administration has been created through the pulmonary administration of an
opioid (or a
combination of opioids) at a rate sufficiently slow to allow for a time gap
between the
onset of side effects and the onset of toxic effects. The rate must also be
slow enough (as
compared to the rate of onset of the opioid) to allow for the onset of side
effects while the
dose is being administered.
In a clinical study relating to this invention, healthy subjects were directed
to
inhale a fentanyl formulation consisting of rapidly acting free fentanyl and
sustained
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
acting liposomal encapsulated fentanyl over 2-20 minutes. In this study,
several subjects
attempted to self limit the dose and required external assistance to receive
the entire dose.
Some subjects self limited the dose because of opioid-induced ventilatory
depression,
with a decrease in ventilation rate reducing the amount of drug inhaled. Other
subjects
self limited the dose because of sedation, and their inability to hold the
device to the
mouth to continue inhaling fentanyl. Some subjects exhibited both side
effects. The trial
demonstrated that patient will, in fact, self limit fentanyl administration
via the
pulmonary route before a toxic level of fentanyl is administered, when 1) the
drug is
intended to be inhaled over a deliberately extended period of time (e.g. 2-20
minutes), 2)
opioid induced ventilatory depression occurs while the drug is being given
(and before a
toxic dose is administered), and/or 3) sedation occurs while the drug is being
given (and
before a toxic dose is administered). We have found that these factors can be
controlled
by designing the rate at which an opioid is given to a patient accordingly.
Preferably, the opioid formulation is administered over 2-20 minutes. The
total
amount of opioid administered over the 2-20 minutes will depend on several
factors,
including the type of opioid or combination of opioids delivered, and the mass
medium
aerodynamic diameter (MMED) of the particles being inhaled. This
administration
period results in a rate of onset to effect that is influenced by the rate of
administration
and affords the patient the ability to involuntarily self limit the dose
through the onset of
ventilatory depression and sedation. We have found that, for an
alfentanyl/morphine
combination drug, a range of 100-500 mcg/min of alfentanyl and 200-1000
mcg/min of
morphine is optimal (measured as drug delivered to the lung of the patient
("systemically
available drug")).
For a free and liposomally encapsulated fentanyl formulation, we have found
that
the levels for systemically available drug to be optimum at 5-50 mcg/min of
free fentanyl
and 15-150 mcg/min of liposomally encapsulated fentanyl. We have found that
nebulized
particles with an MMED of 1-5 microns typically have bioavailability of about
20%,
which means the optimum drug flow from the nebulizer should be between 25-250
mcg/min of free fentanyl and 75-750 mcg/min of microsomally encapsulated
fentanyl.
Our current preferred embodiment of the invention comprises a drug flow from
the
inhaler of 75 mcg/min of free fentanyl and 250 mcg/min of limposomally
encapsulated
fentanyl.
16
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
For other opioid formulations, we expect that a therapeutically equivalent
rate of
systemically available drug to have similar advantages.
In order to prevent peaks of opioid effect that are more potent than the
concentration at which patients stop taking the drug in a multiple opioid
formulation with
at least one rapid-onset opioid and at least one sustained effect opioid, we
expect that the
ratio of sustained-effect opioid to rapid-onset opioid administered should be
less than 1:1
in terms of therapeutic equivalent potency.
Another factor affecting the rate of administration of opioid is the patient's
breating rate. We have found that a breathing rate of 10-15 breaths per minute
(i.e. a
"normal" breathing rate) is preferred.
Opioid response is highly individualized. This reflects, in part, varying
levels of
painful stimulation. In the presence of very severe pain, very high doses of
opioids can be
administered without undue toxicity. Patients being administered chronic
opioids require
higher doses to produce both the desired therapeutic effects and opioid
toxicity. This also
reflects the development of tolerance to opioids. Physicians have sought
improved means
of administering opioids in part because of the wide range of doses required
to adequately
tailor the opioid to the needs of individualized patients.
With the described invention, patients who need large doses of opioids to
provide
analgesia can elect to administer either a larger volume of drug (inhaled over
a longer
period of time), or can be offered a more concentrated solution of drug to be
inhaled over
the expected 2-20 minutes. Either way, the opioid-induced ventilatory
depression and
sedation will still attenuate, and eventually terminate, drug administration
before toxic
doses are inhaled. Preferably, the patient will inhale the drug over a longer
period of time.
Conversely, a patient who requires only a small dose will experience the
desired pain
relief during inhalation. The patient can elect to not inhale additional drug.
The patient
who unwisely continues to self administer opioid despite obtaining the desired
pain relief
will experience ventilatory depression and sedation, which will then either
voluntarily
(according to the instructions given to the patient) or involuntarily'(due to
the side effects
themselves) attenuate and subsequently terminate drug administration before
inhalation of
a toxic dose of opioid. The patient is therefore empowered to self titrate to
analgesic
effect, without a loclcout period and with a lower risk of toxicity.
17
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
The selection of opioid and opioid concentration (as disclosed above, or
otherwise) for the device requires consideration of the time course of opioid
absorption
from the lung into the plasma, and the time course of opioid transfer from the
plasma into
the site of drug effect (e.g., the brain or spinal cord).
Some opioids are associated with very rapid absorption from the lung into the
systemic circulation. For example, the absorption of free fentanyl from the
lung into the
plasma is nearly instantaneous. This would likely be true of remifentanil,
alfentanil, and
sufentanil as well. The absorption of free fentanyl released from the
liposomal
encapsulated fentanyl from the lung to the plasma is far slower.
Some opioids are associated with very rapid transfer from the plasma to the
site of
drug effect. For example, peak alfentanil and remifentanil concentrations at
the site of
drug effect occur within 2 minutes of intravenous-injection. Other opioids are
associated
with very slow transfer from the plasma to the site of drug effect. For
example, the peak
drug effect from an intravenous dose of morphine may be delayed by 10-15
minutes from
the time of the inj ection.
For the self limiting opioid delivery system to work, one of the opioids
should
have both rapid transfer from the lungs to the plasma, and rapid transfer from
the plasma
to the site of opioid drug effect. Fentanyl, alfentanil, sufentanil, and
remifentanil all have
this characteristic (rapid onset). It may be that meperidine and methadone
also have this
effect, but that is not presently known. Although it is possible to obtain the
required
parameters of the invention with a single opioid, we have found that combining
the rapid
onset opioid with a slower acting, but sustained effect opioid gives a
preferred result, as
the patient typically feels analgesic effect for longer periods of time with
such a
combination.
If the desire is to maintain the opioid analgesic effect, then it may be
necessary to
combine the rapid onset opioid with an opioid that has a slower onset, but
sustained
effect. Examples of such formulations include (1) a formulation of fentanyl
and liposomal
encapsulated fentanyl, (2) a formulation of remifentanil, alfentanil,
sufentanil, or fentanyl
in combination with morphine, and (3) a formulation of remifentanil,
alfentanil,
sufentanil, or fentanyl in combination with methadone. Care must be taken to
prevent a
second "peak" of action, at the time of maximum effect of the sustained effect
opioid, that
18
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
is higher than the peak caused by the rapid onset opioid, which allows the
patient to feel
side effects while he or she is administering the drug.
When a rapid onset opioid is combined with an opioid with slow onset and
sustained effect, the concentration of both opioids is adjusted so that the
self limiting
effects of the rapid-onset opioid serves to limit exposure of the patient to
the slow-onset
opioid. The rapid onset opioid acts as an early warning system of sorts,
triggering side
effects in an adequate timeframe.
We have found that side effects are experienced before toxicity is reached.
More
specifically, subjects that experienced side effects at the end of dosing or
shortly after
completion of dosing did not progress to toxic side effects whereas subjects
that
experienced side effects during dosing and continued to inhale drug progressed
to
toxicity, specifically, hypoxia.
As can be appreciated by the above description, creation of the invention
requires
(1) thorough understanding of the pharmacokinetics and pharmacodynamics of one
or
more opioids, and (2) thorough understanding of the relationship between
opioids, carbon
dioxide production and elimination, and ventilation, (3) careful selection of
one or more
opioids, and (4) precise determination of the optimal concentration of each
opioid in the
final formulation in order to achieve the desired clinical profile of the
drug. The final
formulation is determined by pharmacolcinetic and pharmacodynamic modeling of
the
system parameters, with dose optimization performed to find the dose that
exhibits the
best patient safety profile while still providing an adequate analgesic
response.
In the Drawings
Figure 1 is a flow diagram which represents a computer simulation model for
sedation. In all flow diagrams, squares represent amounts, arrows represent
rates
(amounts per unit time), and circles represent either a calculation, rate, or
constant.
Figure 2 is a flow diagram which represents a computer simulation model for
ventilatory depression.
Figure 3 is a flow diagram which represents a computer simulation model for an
inhalation device.
19
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Figure 4 is a flow diagram which represents a computer simulation model for
the
pharmacolcinetic profiling of opioid as administered to a patient through a
pulmonary
route.
Figure 5 is a flow diagram which represents the StellaTM computer simulation
of
the pharmacokinetics of the administration of a single opioid.
Figure 6 is a graph showing output of the StellaTM computer simulation of
Figure
5 (ventilatory depression and sedation models disabled) expressed as a time
course of
quantity of opioid in the inhalation device, and quantity of opioid in the
lung of the
patient. The X axis shows time in minutes. The Y axis shows dose units of
formulation,
in mg. The amount of drug in the inhaler dropped steadily over the first 10
minutes of
stimulation. The amount of drug in the lungs reflects the net processes of
inhalation of
drug into the lungs and absorbtion of drug from the lungs into the systemic
circulation.
Figure 7 is a graph showing the time course of ventilatory depression in the
StellaTM computer simulation of Figure 5 (ventilatory depression and sedation
models
disabled). Ventilatory depression (expressed as a fraction of baseline
ventilation) was
expressed over time of simulation (in minutes).
Figure ~ is a graph showing the time course of quantity of opioid in the
inhalation
device and in the lung of the patient, in the StellaTM computer simulation of
Figure 5
(ventilatory depression model enabled, sedation model disabled). The X axis
shows time
in minutes. The Y axis shows dose units of formulation, in mg. Patient
ventilation
dropped to approximately 25% of baseline ventilation, such depression
persisting for
approximately 5-10 minutes.
Figure 9 is a graph showing the time course of ventilatory depression in the
StellaTM computer simulation of Figure 5 (ventilatory depression model
enabled, sedation
model disabled). Ventilatory depression (expressed as a fraction of baseline
ventilation)
was expressed over time of simulation (in minutes). Change in ventilation
caused by the
self limitation of opioid uptake offers considerable safety to the patient
(compared to
figure 7).
Figure 10 is a graph showing the time course of quantity of opioid in the
inhalation device and in the lung of the patient, in the StellaTM computer
simulation of
Figure 5 (ventilatory depression and sedation models enabled). The X axis
shows time in
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
minutes. The Y axis shows dose units of formulation, in mg. Drug inhalation
stopped
completely at approximately ~ minutes, due to a sedation state being reached
and self
limitation of drug intake.
Figure 11 is a graph showing the time course of ventilatory depression in the
StellaTM computer simulation of Figure 5 (ventilatory depression and sedation
models
enabled). Ventilatory depression (expressed as a fraction of baseline
ventilation) was
expressed over time of simulation (in minutes). Change in ventilation caused
by the self
limitation of opioid uptake from sedation offers considerable safety to the
patient
(compared to figure 7 or 9)
Figure 12 is a flow diagram which represents a computer simulation model for
the
administration of two opioids.
Figure 13 is a flow diagram which represents the StellaTM computer simulation
of
the pharmacokinetics of the admiiustration of two opioids.
Figure 14 is a graph showing the output of StellaTM computer simulation of
Figure
13 expressed as a time course of total quantity of opioid in the inhalation
device and in
the lung of the patient (ventilatory depression and sedation models enabled).
Y axis
shows fentanyl equivalents of formulation in the inhaler (1), of the rapid-
onset opioid in
the lung (2), and the sustained-effect opioid in the lung (3), expressed in
ng/ml (fentanyl
equivalents) of drug over time (in minutes). After approximately 12 minutes,
the patient
stopped inhaling more opioid, reflecting opioid-induced sedation.
Figure 15 is a graph showing the time course of concentration of each opioid
and
of total opioid at the effect site in the StellaTM computer simulation of
Figure 13
(ventilatory depression and sedation models enabled). Amount of rapid-onset
opioid (1),
sustained-effect opioid (2) and the combination effect of both the rapid-onset
opioid and
the sustained-effect opioid (3) at the site of effect were shown, in ng/ml of
fentanyl
equivalents, over time (in minutes).
Figure 16 is a graph showing the time course of ventilatory depression during
and
after delivery of opioids in the StellaTM computer simulation of Figure 13
(ventilatory
depression and sedation models enabled). Ventilatory depression (expressed as
a fraction
of baseline ventilation) was expressed over time of simulation (in minutes).
The
21
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
combination of the two opioids reaches a peals during the administration of
the first
opioid.
Figure 17 is a flow diagram which represents the StellaTM computer simulation
of
the pharmacokinetics of the administration of two opioids, where the two
opioids being
administered are alfentanil and morphine.
Figure 18 is a graph showing the time course of concentration of alfentanil,
morphine, and combined opioid at the effect site in the StellaTM computer
simulation of
Figure 17 (ventilatory depression and sedation models enabled). Line 1 shows
concentration of alfentanil; line 2 shows concentration of morphine, and line
3 shows
combined concentration. All drug levels are shown at the site of effect, and
expressed in
ng/ml of fentanyl equivalents over time (in minutes). Drug administration was
terminated
after delivery of 90% of the drug because of patient sedation. As seen in line
3, the
highest opioid exposure occurs during inhalation.
Figure 19 is a graph showing the time course of ventilatory depression in the
StellaTM computer simulation of Figure 17 (ventilatory depression and sedation
models
enabled). Ventilatory depression (expressed as a fraction of baseline
ventilation) was
expressed over time of simulation (in minutes). Ventilation decreases to about
65% of
baseline during drug administration.
Figure 20 is a graph showing maximum concentration of opioid in the plasma
against end of dose concentration of opioid in the plasma of patients
administered opioid.
Figure 20A shows patients administered with a combination of fentanyl and
liposomally
encapsulated fentanyl through a pulmonary route. Figure 20B shows patients
administered with fentanyl intravenously. Maximum concentration of opioid was
not
significantly higher than the concentration at end of dose, indicating that if
the "end of
dose" amount is non-toxic, the maximum concentration of opioid taken by the
subject is
likely also non-toxic.
Figure 21 is a graph showing time to side/toxic effect versus time to end of
dose
for the side effects and toxic effects of patients administered a combination
of fentanyl
and liposomally encapsulated fentanyl through a pulmonary route. In all cases,
time to
toxicity was equal to or longer than time to side effect.
22
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Figure 22 is a table showing the statistical correlation of side effect to
toxic effect. Side
effect is correlated to toxic effect at a p<.04.
Examples
The examples below are designed to demonstrate but not limit the embodiments
of
the present invention.
Example 1' Theoretical Model for Opioid Delivery
Examples 2-4 are based on a theoretical model for opioid delivery; this
theoretical
model is described for greater certainty here in Example 1.
The theoretical model for opioid delivery was programmed into the computer
simulation package "Stella" (High Performance Systems, Lebanon, NH). The
elements
shown in this example, both in figures and in text, are adapted from the
Stella model
representation, and explain both the programming of the simulation, and how
the
simulation works.
hl the figures, rectangles represent variables that indicate accumulation of a
substance (with exceptions noted below). Open arrows represent flow into or
out of the
accumulators, and closed arrows represent the elements that control the flow.
Some
closed arrows are omitted for simplicity of representation. Ovals represent
model
parameters (inputs) and time-independent calculations. Many model parameters
and
constants were obtained from the prior art (see Scott JC, Stanski DR Decreased
fentanyl
and alfentanil dose requirements with age. A simultaneous pharmacolcinetic and
pharmacodynamic evaluation. J Pharmacol Exp Ther. 197 Jan;240(1):159-66).
(a) Sedation Model
A model for opioid induced sedation was designed (Fig. 1 - Sedation Model).
Opioid in Effect Site 1010 was used as a variable denoting the concentration
of opioid at
the site of drug effect. If more than 1 opioid was present at the site of drug
effect, Opioid
in Effect Site 1010 was built to represent the sum of the opioids present,
each normalized
to their relative potency (for example, in Examples 3 and 4, below).
Sedation Threshold 1020 was defined as the Opioid Concentration 1010 that
would render the patient unable to use the inhaler. Sedation Threshold 1020
was
23
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
determined either through experimentation or through the known
pharmacolcinetics of the
opioid.
Sedation Evaluator 1030 was a test of whether Opioid Concentration 1010
exceeded Sedation Threshold 1020. If Opioid Concentration 1010 exceeded
Sedation
Threshold 1020, Sedation Evaluator converted the value of Sedation State 1040
from 0 to
1. Sedation State 1040 was an exception to the rule that rectangles represent
accumulation of a substance: Instead, the role of Sedation State 1040 within
the model
was that of a memory component, which would remember that the opioid had
exceeded
the sedation threshold. In subsequent models, data from Sedation State 1040
functioned to
turn off further administration of opioids, simulating patient sedation and
the resulting
removal of the inhaler from the mouth.
(b) Trehtilatory Depression Model
A Ventilatory Depression simulation was programmed (Fig. 2). In this model,
C02 was produced by the metabolic activity of the body at a rate C02
Production 2010,
flowed into the plasma, (Plasma CO2 2020). C02 Production 2010 was either
determined
experimentally, or known from prior art (see, for example, Bouillon T, Schmidt
C,
Garstka G, Heimbach D, Stafforst D, Schwilden H, Hoeft A. Pharmacokinetic-
pharmacodynamic modeling of the respiratory depressant effect of alfentanil.
Anesthesiology. 1999 Ju1;91(1):144-55 and Bouillon T, Bruhn J, Radu-Radulescu
L,
Andresen C, Cohane C, Shafer SL. A model of the ventilatory depressant potency
of
remifentanil in the non-steady state. Anesthesiology. 2003 Oct;99(4):779-~7.).
Plasma
C02 2020 equilibrated with the CO2 in the brain (Brain C02 2040) at a rate
(Brain
Plasma C02 Equilibrium 2030). CO2 was eliminated from the plasma in a manner
simulating the exhalation of air from the lungs, at a rate C02 Elimination
2050 that was
mediated by the parameter Ventilatory Depression 2060.
Ventilatory Depression 2060 increased as the opioid concentration at the site
of
drug effect (Opioid in Effect Site 1010) increased. Ventilatory Depression
decreased the
elimination of C02 from the lungs (C02 Elimination 2050), causing C02 to rise
in the
brain, (Brain C02 2040). As Brain C02 2040 increased, it stimulated
ventilation through
a negative effect on Ventilatory Depression 2060, offsetting in part the
depressant effects
of Opioid in Effect Site 1010, which has a positive effect on Ventilatory
Depression 2060.
24
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Other parameters were designed to effect Ventilatory Depression 2060; the sum
of
these parameters were illustrated in this model as Model Parameters 2070;
parameters
comprising Model Parameters 2070 were described in greater detail in Figure 5.
These
Model Parameters 2070 effect Ventilatory Depression 2060, which in turn
effects C02
Elimination 2050 and Brain C02 2040.
Although the programming of this simulation into Stella is novel, the
Ventilatory
Depression Model is known in the art, and is referred to as an "Indirect
Response Model."
(c) Device Model
A model for the inhalation device is shown in Figure 3. Dose 3050 represents
the
total amount of opioid added to the Inhaler. Opioid Dose 3050 is added to the
inhaler at a
rate Fill Inhaler 3010. This rate is required for the working of the
simulation, but is
calculated at an instantaneous rate. Formulation In Inhaler 3020 represents
the opioid
contained within the inhaler. The patient inhales the formulation at a rate of
inhalation
(Inhalation 3030) into the lungs, (Formulation in Lungs 3040). Inhalation 3030
is effected
by Ventilatory Depression 2060 and Sedation State 1040. Specifically,
Inhalation 3030 is
slowed by the increase of Ventilatory Depression 2060. For example, if
Ventilatory
Depression 2060 was 50% of baseline, then drug was inhaled at half the
baseline rate
(Inhalation 3030 was half baseline). However, if Sedation State 1040 = l, then
inhalation
of drug into the lungs ends, and no further drug is inhaled.
(d) t~hczr~ac~c^kiraetie Model
A Pharmacokinetic Model for systemic opioid was programmed. Formulation In
Lungs 3040 was absorbed systemically at a rate Systemic Absorption 4010 into
the blood
plasma (Opioid in Plasma 4020). Opioid in Plasma 4020 equilibrated at a rate
Plasma-
Effect Site Drug Equilibrium 4030 with opioid at the site of drug effect
(Opioid in Effect
Site 1010). Opioid also redistributed into tissue Opioid in Tissue 4060 at a
rate Opioid
Redistribution 4050 or was eliminated from the plasma at a rate Opioid
Elimination
4070. Opioid in Tissue 4060 and Opioid Redistribution 4050 were programmed as
optional parameters that could be used or not used depending on the
pharmacolcinetic
model of the particular opioid utilized. The rates Systemic Absorption 4010,
Plasma-
Effect Site Drug Equilibrium 4030, Opioid Elimination 4070, and Opioid
Redistribution
4050 were all determined by a vector of pharmacolcinetic parameters of the
particular
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
opioid being administered, represented in the model as Opioid Pharmacolcinetic
Parameters 4080, and calculated by pharmacokinetic modeling.
Although the programming of this simulation into Stella was novel, the
Pharmacolcinetic Model is known in the art, and is referred to as a
"Mammillary
Pharmacolcinetic Model With An Effect Site." Mammillary models as represented
above
typically have 0, 1 or 2 tissue compartments, yielding models referred to as
1, 2, or 3
Compartment Models with an effect site, respectively.
Example 2: Administration of a Sin 1~ a Opioid
This example is an application of Example 1: Theoretical Model for Opioid
Delivery. This example is meant to illustrate the Theoretical Model for Opioid
Delivery
in use; the model parameters do not reflect any specific opioid. Instead, the
model
parameters in this example have been designed to clearly demonstrate the self
limiting
aspect of the proposed system of opioid delivery. This Example shows the
integration of
the four simulations as described in Example 1, and output from the model when
the
simulation is run.
(a) Inte~~cz~zora of'the llsl^del
Figure 5 shows the elements of the model as described in Example 1, wherein a
single opioid is administered through inhalation. Figure 5 encompasses: a
Device Model
5010 that is equivalent to the Device Model shown and explained in Example 1
as the
whole of Figure 3; a Pharmacolcinetic Model 5020 that is equivalent to the
Pharmacokinetic Model shown and explained in Example 1 as the whole of Figure
4
(with the exception of the exclusion of optional parameters Opioid in Tissue
4060 and
Opioid Redistribution 4050, and with the further exception that Opioid
Pharmacokinetic
Parameters 4080 were built into Systemic Absorbtion 4010, Opioid Elimination
4070,
and Plasma Effect Site Equilibration 4030, and not shown as a separate
parameter - see
source code for more information); a Ventilatory Depression Model 5030, which
was
equivalent to the Ventilatory Depression Model shown and explained in Example
1 as the
whole of Figure 2 (with the exception that Model Parameters 2070 are shown in
`expanded' form, with various elements comprising Model Parameters 2070,
namely
PAC02@0 2071, Ke1C02 2072, lce0C02 2073, C50 2074, Gamma 2075, and F 2076,
shown; and a Sedation Model 5040, that is equivalent to the Sedation Model
shown in
26
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Figure 1. The mechanics of these four models were described in depth in
Example 1,
with the exception of the expansion of Model Parameters 2070, the mechanics of
which
are explained as follows:
Baseline C02 2071 is the C02 at baseline, prior to administration of opioid.
lcel C02
2072 is the elimination rate relating Plasma C02 2020 to C02 Elimination 2050,
so
that at baseline (i.e., in the absence of ventilatory depression):
C02 Elimination 2050 = kel C02 2072 x Plasma C02 2020
It follows that at baseline, carbon dioxide in the body is at steady state,
and hence the
C02 Elimination 2050 = C02 Production 2010. This permits calculation of the
rate of
C02 production (which is constant) in terms of Baseline C02 2071 and kel C02
2072
as:
C02 Production 2010 = kel C02 2072 x Baseline Plasma C02 2071.
The rate of Brain Plasma Equilibration 2020 is determined by the parameter
lce0 C02
2073, so that:
Brain Plasma Equilibration 2020 = ke0 CO2 2073 x (Plasma CO2 2020 - Brain CO2
2040)
Opioids depress ventilation as a sigmoidal function of the Opioid in the
Effect Site,
1030, and the parameters C50 2074, the opioid concentration associated with
50% of
maximum effect, and gamma 2075, the steepness of the concentration vs.
response
relationship, with the contribution of the opioid to ventilatory depression
expressed as:
Opioid in the effect site 1030ga"""azo~s
1-
C50 2074g~"""a Zo's + Opioid in the effect site 1 O3Ogann,a 2075
Conversely, carbon dioxide stimulations ventilation. The increase in
ventilation can be
modeled as a function of Baseline C02 2071, Brain C02 2040, and F 2076, a
parameter describing the steepness of the relationship:
Brain C02 2040 F 2076
C Baseline C02 2071
Putting these together, Ventilatory Depression 2060 can be described as:
27
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Ventilatory depression 2060=
_ Opioid in the effect site 1030ga"""a2o's Brain C02 2040 F207G
1 C50 2074ga"'"'azo~s +O ioid in the effect site 1030ga"""azo~s x Baseline C02
2071
C
p
With ventilatory depression 2060 now defined, we can fully define C02
Elimination
2050 in the presence of opioid induced ventilatory depression as:
C02 Elimination 2050 = kel C02 2072 x Plasma C02 2020 x Ventilatory Depression
2060
completing the description of the model.
In this manner, the models from Example 1 were combined into one model of
opioid effect. This model, shown in Figure 5, can also be described by the
following
mathematical model, as represented in the Stella programming language (source
code):
Brain C02 2040(t) = Brain C02 2040(t - dt) + (Brain Plasma C02 Equilibration
2020) * dt
INIT Brain C02 2040 = Baseline C02 2071
INFLOWS:
Brain Plasma C02`Equilibration 2020 = ke0 C02 2073 *(Plasma C02._2020-
Brain C02 2040)
Formulation in Inhaler 3020(t) = Formulation in Inhaler 3020(t - dt) + (Fill
Inhaler 3010 -
Inhalation 3030) * dt
INIT Formulation in Inhaler 3020 = 0
INFLOWS:
Fill Inhaler 3010 = if time = 0 then Dose 3050/DT else 0
OUTFLOWS:
Inhalation 3030 = If Sedation State_1040 = 0 then .5*(Ventilatory Depression
2060) else 0
Formulation in Lung 3040(t) = Formulation in Lung 3040(t - dt) + (Inhalation
3030 -
Systemic Absorption 4010) * dt
INIT Formulation in Lung 3040 = 0
INFLOWS:
Inhalation 3030 = If Sedation State_1040 = 0 then .5*(Ventilatory Depression
2060) else 0
OUTFLOWS:
Systemic Absorption 4010 = Formulation in Lung 3040*.69311
28
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Opioid in Effect Site 1010(t) = Opioid in_Effect Site_1010(t - dt) +
(Plasma Effect Site Equilibration 4030) * dt
INIT Opioid in Effect Site 1010 = 0
INFLOWS:
Plasma Effect Site Equilibration 4030 = (Opioid in Plasma 4020-
Opioid in Effect Site_1010)*.693/1
Opioid in Plasma 4020(t) = Opioid in Plasma 4020(t - dt) + (Systemic
Absorption 4010 -
Opioid Elimination 4070 - Plasma Effect Site Equilibration 4030) * dt
INIT Opioid in Plasma 4020 = 0
1 O INFLOWS:
Systemic Absorption 4010 = Formulation in Lung 3040*.693/1
OUTFLOWS:
Opioid Elimination 4070 = Opioid in Plasma 4020*.693/10
Plasma Effect Site Equilibration 4030 = (Opioid in Plasma 4020-
Opioid in Effect Site 1010)*.693/1
Plasma C02 2020(t) = Plasma C02 2020(t - dt) + (C02 Production 2010 -
Brain Plasma C02 Equilibration 2020 - C02 Elimination 2050) * dt
INIT Plasma C02 2020 = Baseline C02 2071
INFLOWS:
C02 Production 2010= Baseline C02 2071*kelC02 2072
OUTFLOWS:
Braid Plasma C02 Equilibration 2020 = ke0 C02 2073 *(Plasma C02 2020-
Brain C02 2040)
C02 Elimination 2050=Plasma C02 2020*kelC02 2072*Ventilatory Depression 2060
Sedation State_1040(t) = Sedation State_1040(t - dt) + (Sedation Evaluator
1030) * dt
INIT Sedation State 1040 = 0
INFLOWS:
Sedation Evaluator 1030 = if(Opioid in Effect Site_1010>Sedation Tlweshhold
1020) then 1
else 0
Baseline C02 2071 =40
CSO 2074 = .3
29
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Dose 3050 = 5
F 2076 = 4
Gamma 2075 = 1.2
ke0 C02 2073 = 0.92
ke1C02 2072 = 0.082
Sedation Threshhold 1020 =1.5
Ventilatory Depression 2060 = (1
Opioid in Effect Site-1010^Gamma 20751(C50 2074^Gamma 2075+Opioid in Effect
Site-10
10^Gamma 2075))*(Brain C02 2040Baseline C02 2071)^F 2076
(b) Output of the model when run with Ventilatory Depression Model and
Sedation
Model Disabled
The model designed and described in (a) was run as a simulation of opioid
effect,
using the following initial parameters: Formulation In Inhaler 3020 = 5
milliliters at time
= 0. The model was allowed to run over a time course of two hours. For this
simulation,
the feedbaclc loop on drug uptake aspects of the Ventilatory Depression Model
(i.e. the
feedback of the effect of Ventilatory Depression 2060 on Device Model 5010),
and the
Sedation Model were disabled. Output of the model, when run, was plotted for
various
parameters in Figures 6 and 7.
Figure 6 shows the output of the model as run in the absence of patient self
limiting inhalation of opioid (i.e. with the Ventilatory Depression Model and
the Sedation
Model disabled). Figure 6 shows the time course of drug in the inhaler
(Formulation In
Inhaler 3020 - line 1), and in the lungs (Formulation in Lungs 3040 - line 2)
in the
absence of the self limiting aspects of the invention. The amount of drug in
the inhaler
dropped steadily over the first 10 minutes of simulation, at a rate Inhalation
3030. The
amount of drug in the lungs reflected the net processes of inhalation of drug
into the
lungs, and absorption of drug from the lungs into the systemic circulation.
Figure 7 shows Ventilatory Depression 2060 over time, for the same simulation
(Ventilatory Depression Model and Sedation Model disabled). The graph output
indicated that patient's ventilation dropped to approximately 25% of baseline
ventilation
in this simulation. The ventilatory depression persisted for approximately 5-
10 minutes.
The drop in ventilation was reversed as carbon dioxide built up in the
patient's plasma,
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
and, at the same rate, the patient's lungs (not simulated), counteracting the
depressant
effect of the opioid on ventilation. This drop in ventilation exposed the
patient to risk
from injury from hypoxia.
(c) Output of tlae model when run with hentilatory Depression Model enabled
The simulation used in (b) was modified by enabling the Ventilatory Depression
Model, and run again with the same initial parameters of Formulation In
Inhaler 3020 = 5
milliliters at time 0. Output of various parameters were plotted over time.
Figure 8 shows
Formulation In Inhaler 3020 (line 1), depicting the amount of drug that is
left in the
inhaler, and Formulation In Lungs 3040 (line 2), depicting the amount of drug
in the
lungs, in the presence of ventilatory depression, one of the two self limiting
aspects of the
invention (the other being sedation). As compared to Example 2(b), as
expected, it took
longer to inhale the drug when the simulation was run with the Ventilatory
Depression
Model enabled - inhalation of drug in Figure 8 took place over approximately
17 minutes
as opposed to the 10 minutes in Figure 6. This was due to a reduction in
ventilation
caused by ventilatory depression, which limited the patient's exposure to the
opioid. This
reduction in ventilation was best illustrated in Figure 9, which plotted
Ventilatory
Depression 2060 over time for the same simulation. Ventilatory Depression 2060
was
depressed by 50% in Figure 9. When compared with the simulation shown in
Figure 7,
the patient was breathing half as much (in Figure 9) as when simulation was
run with the
Ventilatory Depression Model deactivated (in Figure 7). This simulation shows
that the
change in ventilation caused by the self limitation of opioid uptake offers
considerable
safety to the patient.
(d) Output of the model when gun with Ventilatory Depression Model and
Sedation
Model eraabled
The same simulation (Formulation In Inhaler 3020 = 5 milliliters at time = 0)
was
run, this time with both the Ventilatory Depression Model 5030 and the
Sedation Model
5040 enabled. Output of various parameters were plotted, over time. Figure 10
shows the
time course of Formulation In Inhaler 3020 (Line 1) and Formulation In Lungs
3040
(Line 2) in the presence of ventilatory depression and sedation. As seen in
the figure,
after 8 minutes drug inhalation stopped completely. The reason was that the
patient has
become sedated, and could no longer hold the inhaler to the mouth (simulated
here as
Sedation State 1040 turning from 0 to 1). At this time, approximately 2
milliliters
31
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
remained in Formulation In Inhaler 3020, and therefore, approximately 40% of
the opioid
dose remained in the inhaler and was not inhaled. Figure 11 plots Ventilatory
Depression
2060 during the time course of this simulation. The maximum depression of
ventilation
in Figure 11 was approximately 60%. When compared with Figure 9, the improved
safety
from the opioid-induced sedation is evident.
Thus, Example 2, as illustrated in Figures 5 through 11, demonstrate through
simulation the effects and advantages of the self limiting system of opioid
delivery, as
described herein.
Example 3: Administration of two o ip oids
In this simulation, the model parameters do not reflect any specific opioids,
but
have been adjusted to demonstrate clearly the self limiting aspect of the
proposed system
of opioid delivery. The simulation models and measures the same variables,
this time for
an opioid composition comprising of two different opioids with different
pharmacokinetics.
(a) Building a tw^ opi^id rya^del.
Figure 12 addresses how two opioids are combined into a single opioid
concentration for the model. In the two opioid simulation, Rapid Opioid In
Effect Site
12010 represents the concentration of rapid onset opioid; Slow Opioid In
Effect Site
12020 represents the slow onset opioid. Each of these is determined in
parallel and in the
same manner as in the one opioid model (Example 2). However, each is
determined
separately, then combined to determine Combined Opioid Effect Site
Concentration
12030. Combined Opioid Effect Site Concentration 12030 is calculated using the
known
relative potency of each opioid, Relative Potency 12040. Combined Opioid
Effect Site
Concentration 12030 is equal to, and depicted as, Opioid in effect Site 1010
in the two
opioid models illustrated in Figures 13 and 17.
Figure 13 illustrates the algorithm for the two opioid model simulation. It
encompasses: a Device Model 13010, equivalent to and illustrated as Device
Model 5010
and as described in Examples 1 and 2; a Pharmacokinetic Model 13020 comprising
a
combination of two instances of the Pharmacolcinetic Model 5020 (one for the
rapid
opioid, and one for the slow opioid), each as illustrated in Figure 4 and
Figure 5, and as
described in Examples 1 and 2, and each running in parallel, then combined
using the
32
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Two Drug Model 13050, as described in Figure 12; a Ventilatory Depression
Model
5030, as illustrated in Figure 2 and Figure 5, and as described in Examples 1
and 2; and a
Sedation Model, 5040, as illustrated in Figure 2, Figure 5, and as described
in Examples 1
and 2.
The model shown in figure 13 can also be described by the following
mathematical model, as represented in the Stella programming language (source
code).
Brain C02 2040(t) = Brain C02 2040(t - dt) + (Brain Plasma C02 Equilibration
2020) * dt
INIT Brain C02 2040 = Baseline C02 2071
INFLOWS:
Brain Plasma C02 Equilibration 2020 = ke0 C02 2073 *(Plasma C02 2020-
Brain C02 2040)
Formulation in Inhaler 3020(t) = Formulation in Inhaler 3020(t - dt) + (Fill
Inhaler 3010 -
Inhalation 1 3031 - Inhalation 2 3032) * dt
INIT Formulation in Inhaler 3020 = 0
INFLOWS:
Fill Inhaler 3010 = if time = 0 then Dose 3050/DT else 0
OUTFLOWS:
Inhalation 1^3031 = if Sedation State 1040 = 0 then 0.25*Ventilatory-
Depression else 0
Inhalation 2 3032 = if Sedation State-1040 = 0 then 0.25*Ventilatory
Depression 2060 else 0
Opioid in Effect Site_1010(t) = Opioid in Effect Site-1010(t - dt)
INIT Opioid in Effect Site 1010 = 0
Plasma C02 2020(t) = Plasma C02 2020(t - dt) + (C02 Production 2010 -
Brain Plasma C02 Equilibration 2020 - C02 Elimination 2050) * dt
INIT Plasma C02 2020 = Baseline C02 2071
INFLOWS:
C02 Production 2010 = { Place right hand side of equation here... }
OUTFLOWS:
Brain Plasma C02 Equilibration 2020 = ke0 C02 2073*(Plasma C02 2020-
Brain C02 2040)
C02 Elimination 2050 = Plasma C02 2020*kelC02 2072*Ventilatory Depression 2060
33
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Rapid Drug Effect Site(t) = Rapid Drug Effect Site(t - dt) +
(Rapid Drug Plasma Effect Site Equilibration) * dt
INIT Rapid Drug Effect Site = 0
INFLOWS:
Rapid Drug Plasma Effect Site Equilibration = (Rapid Drug In Plasma-
Rapid Drug Effect Site)*.693/1
Rapid Drug In Plasma(t) = Rapid Drug In Plasma(t - dt) + (Rapid Drug
Absorption -
Rapid Drug Clearance - Rapid Drug Plasma Effect Site Equilibration) * dt
INIT Rapid Drug In Plasma = 0
INFLOWS:
Rapid Drug Absorption = Rapid Formulation in Lung*.693/1 *Rapid Drug
Concentration
OUTFLOWS:
Rapid Drug Clearance = Rapid Drug In Plasma*.693/10
Rapid Drug Plasma Effect Site Equilibration = (Rapid Drug In Plasma-
Rapid Drug Effect Site)*.693/1
Rapid Formulation in Lung(t) = Rapid Formulation in Lung(t - dt) + (Inhalation
1 3031 -
Rapid Drug Absorption) * dt
INIT Rapid Formulation in Lung = 0
INFLOWS:
Inhalation 1 3031 = if Sedation State 1040 = 0 then 0.25*Ventilatory
Depression else 0
OUTFLOWS:
Rapid Drug Absorption = Rapid Formulation in Lung*.693/1 *Rapid Drug
Concentration
Sedation State_1040(t) = Sedation State_1040(t - dt) + (Sedation Evaluator
1030) * dt
INIT Sedation State 1040 = 0
INFLOWS:
Sedation Evaluator 1030 = if(Opioid in Effect Site_1010>Sedation Threshhold
1020) then 1
else 0
Slow Drug Effect Site(t) = Slow Drug Effect Site(t - dt) +
(Slow Drug Plasma Effect Site Equilibration) * dt
INIT Slow Drug Effect Site = 0
INFLOWS:
34
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Slow Drug Plasma Effect Site Equilibration = (Slow Drug In Plasma-
Slow Drug Effect Site)*.693/10
Slow Dnig In Plasma(t) = Slow Drug In Plasma(t - dt) + (Slow Drug Absorprion -
Slow Drug Clearance - Slow Drug Plasma Effect Site Equilibration) * dt
INIT Slow Drug In Plasma = 0
INFLOWS:
Slow Drug Absorption = Slow Formulation In Lung*.693/12*Slow Drug
Concentration
OUTFLOWS:
Slow Drug Clearance = Slow Drug In Plasma*.693/300
Slow Drug Plasma Effect Site Equilibration = (Slow Drug In Plasma-
Slow Drug Effect Site)*.693/10
Slow Formulation In Lung(t) = Slow Formulation In Lung(t - dt) + (Inhalation 2
3032 -
Slow Drug Absorption) * dt
INIT Slow Formulation In Lung = 0
INFLOWS:
Inhalation 23032 = if Sedation State-104.0 = 0 then 0.25''°Ventilatory
Depression 2060 else 0
OUTFLOWS;
Slow Drug Absorption = Slow Formulation In Lung*.693/12*Slow Drug
Concentration
Baseline C02 2071 = 40
C50 2074 = .3
Dose 3050 = 5
F 2076 = 4
Gamma 2075 = 1.2
ke0 C02 2073 = 0.92
ke1C02 2072 = 0.082
Opioid in Effect Site_1010 = Rapid Drug Effect Site+Slow Drug Effect Site
Rapid Drug Concentration = 1
Sedation Threshhold 1020 = 1.5
Slow Drug Concentration = 1
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Ventilatory Depression 2060 = (1-
Opioid in Effect Site 1010^Gamma 2075/(C50 2074^Gamma 2075+Opioid in Effect
Site 1010^Gam
ma 2075))*(Brain C02 2040Baseline C02 2071)^F 2076
(b) Output of model when run witla yentilatory Depression Model and Sedation
Model
enabled
The same simulation (Formulation In Inhaler 3020 = 5 milliliters at time = 0)
was
run in the two opioid model as illustrated in Example 3(a) and Figure 13.
Figure 14
shows the time course of Formulation In Inhaler 3020 (Line 1), Formulation In
Lung
(Rapid Opioid) 3040 (Line 2), and Formulation In Lung (Slow Opioid) 3040 (Line
3), in
the presence of ventilatory depression and sedation. The simulation showed
that, over 12
minutes of run, the drug was inhaled by the patient. The rate of fall in the
amount of drug
in the inhaler was not perfectly linear, reflecting the slowed breathing with
opioid-
induced ventilatory depression. After approximately 12 minutes, the patient
stopped
inhaling more opioid, reflecting opioid-induced sedation. The rapidly acting
opioid was
quickly taken up into the systemic circulation, which limited how much
accumulated in
the lung, and produced a quick drop in concentration in the lung when the
patient stopped
inhaling more opioid. The slowly acting ^pioid was taken up slowly by the
lung, which
permitted more drug to accumulate in the lung during inhalation, and the
administration
of opioid into the systemic circulation for over two hours following the end
of opioid
delivery to the patient.
Figure 15 shows different variables for the same simulation. In Figure 15,
line 1
indicates the rapidly acting opioid concentration in the effect site (Rapid
Drug Effect
Site), over time, and demonstrates the rapid rise owing to quick absorption
and rapid
plasma-effect site equilibration, and a rapid drop owing to rapid metabolism.
Line 2 is the
slowly acting opioid concentration in the effect site (Slow Drug Effect Site),
over time,
and demonstrated a slow rise in concentration owing to slow absorption and
slow plasma
effect site equilibration, and a slow decrease over time owing to slow
metabolism. Line 3
shows the combined concentration of rapid and slow onset drug (Combined Opioid
Effect
Site Concentration) As can be seen, the combination reaches a peak during the
administration of the first opioid.
Figure 15 and Figure 14 show different variables for the same simulation run,
on
the same X axis (time). One can therefore refer back to Figure 14 to see that
the patient
36
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
stopped self administering drug at approximately 12 minutes. When Figure 14 is
interposed with Figure 15, we can see that this reflected the patients'
response to the
rapidly acting opioid, as the concentration of the slowly acting opioid was
negligible at 12
minutes. However, the overall opioid concentration remained fairly steady over
time.
This reflected the slowly acting opioid gradually replacing the rapid acting
opioid in
Opioid In The Effect Site as the rapidly acting opioid was eliminated from the
system
through Rapid Drug Clearance.
Figure 16 shows the time course of Ventilatory Depression 2060 during and
after
delivery of opioids with the two-opioid delivery system, in the same
simulation run.
Figure 16 illustrates an initial decrease in ventilation to approximately 60%
of baseline.
As mentioned previously (in the description for Figure 11), this is well
tolerated by
patients. As the C02 builds up, ventilation was stimulated. Note that there
was very little
decrease in ventilation after this initial drop. The reason is that there is
now adequate C02
accumulation in the patient to continue driving ventilation.
As demonstrated by figures 13, 14, and 15, in the two drug embodiment of the
device, the first drug acts as a `probe' of the patient's sensitivity to
opioids, and limits the
dose of both the first and the second opioid. In this manner, the patient can
receive an
slowly acting opioid without receiving an excessive dose. A combination of two
opioids,
one of them fast acting, can therefore be used to increase the safety profile
of either
opioid alone, or, more particularly, of the slow acting opioid.
Example 4: Alfentanil and Morphine as examples of opioids in the two drvt
model
This example shows an application of Example 3 to two specific drugs, namely,
alfentanil and morphine, wherein alfentanil is the rapidly acting opioid and
morphine is
the slowly acting opioid.
Figure 17 encompasses: a Device Model 17010, comprising 2 Device Model
5010's, as described in Figure 5 and explained in Example l, and each running
in parallel,
but each modified and re-labeled for the specific known parameters of the
opioids
alfentanil and morphine; a Ventilatory Depression Model 5030, as described in
Figure 2,
a Sedation Model 5040, as described in Figure 1, and a Two Drug Model, 17050,
as
described in figure 12 but re-labeled to reflect the specific drugs alfentanil
and morphine.
Figure 17 exposes all of the parameters 2070 of the ventilatory depression
model, 17030.
37
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
The parameters 4080 of the pharmacokinetic models for morphine and alfentanil,
17020,
are now fully exposed. Alfentanil and morphine are each represented by a 3
compartment
mammillary model with an effect site.
The model shown in figure 17 can also be described by the following
mathematical model, as represented in the Stella programming language. The
constants
for alfentanil and morphine are based on existing literature for these drugs.
Alfentanil in Inhaler(t) = Alfentanil in Inhaler(t - dt) + (- Inhale
Alfentanil) * dt
INIT Alfentanil in Inhaler = Alfentanil Dose ug
OUTFLOWS:
Inhale Alfentanil = If Sedation State = 0 then
Alfentanil Dose ug/Dose Duration*Ventilatory Depression else 0
Alfentanil in Lung(t) = Alfentanil in Lung(t - dt) + (Inhale Alfentanil -
Alfentanil Uptake) * dt
INIT Alfentanil in Lung = 0
INFLOWS:
Inhale Alfentanil = If Sedation State = 0 then
Alfentanil Dose ug/Dose Duration*Ventilatory Depression else 0
OUTFLOWS:
Alfentanil Uptake = Alfentanil in Lung*.693/Alfentanil Absorption Half Life
Alfentanil X 1 (t) = Alfentanil X 1 (t - dt) + (Alfentanil Cl2 + Alfentanil
Cl3 + Alfentanil CLe +
Alfentanil Uptake - Alfentanil Cll) * dt
INIT Alfentanil X1 = 0
INFLOWS:
Alfentanil C12 = Alfentanil X2*Alfentanil K21-Alfentanil X1*Alfentanil K12
Alfentanil Cl3=Alfentanil X3*Alfentanil K31-Alfentanil X1*Alfentanil K13
Alfentanil CLe = Alfentanil Xeffect*Alfentanil Ke0-
Alfentanil X1*Alfentanil Ke0*.001/Alfentanil V1
Alfentanil Uptake = Alfentanil in Lung*.693/Alfentanil Absorption Half Life
OUTFLOWS:
Alfentanil Cll =Alfentanil X1*Alfentanil K10
Alfentanil X2(t) = Alfentanil X2(t - dt) + (- Alfentanil C12) * dt
INIT Alfentanil X2 = 0
38
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
OUTFLOWS:
Alfentanil C12 = Alfentanil X2*Alfentanil K21-Alfentanil X1 *Alfentanil K12
Alfentanil X3(t) = Alfentanil X3(t - dt) + (- Alfentanil Cl3) * dt
INIT Alfentanil X3 = 0
OUTFLOWS:
Alfentanil Cl3 =Alfentanil X3*Alfentanil K31-Alfentanil Xl*Alfentanil K13
Alfentanil Xeffect(t) = Alfentanil Xeffect(t - dt) + (- Alfentanil CLe) * dt
INIT Alfentanil Xeffect = 0
OUTFLOWS:
Alfentanil CLe = Alfentanil Xeffect*Alfentanil Ke0-
Alfentanil Xl*Alfentanil Ke0*.001/Alfentanil Vl
Morphine in Inhaler(t) = Morphine in Inhaler(t - dt) + (- Inhale Morphine) *
dt
INIT MorphW a in Inhaler = Morplune Dose mg* 1000
OUTFLOWS:
Inhale Morphine = If sedation state = 0 then
Morphine Dose mg*1000/Dose Duration°Ventilatory Depression else 0
Morphine in Lung(t) = Morphine in Lung(t - dt) + (Inhale Morphine - Morphine
Uptake) * dt
INIT Morphine in Lung = 0
INFLOWS:
Inhale Morphine = If sedation state = 0 then
Morphine Dose mg*1000/Dose Duration*Ventilatory Depression else 0
OUTFLOWS:
Morphine Uptake = Morphine in Lung*.693/Morphine Absorption Half Life
Morphine X1(t) = Morphine X1(t - dt) + (Morphine Cl2 + Morphine C13 + Morphine
CLe +
Morphine Uptake - Morphine Cll) * dt
INIT Morphine^X 1 = 0
INFLOWS:
Morphine Cl2 = Morphine X2*Morphine K21-Morphine Xl *Morphine K12
Morphine C13 =Morphine X3*Moiphine K31-Morphine Xl*Morphine K13
Morphine CLe = Morphine Xeffect*Morphine Ke0-
Morphine X1*Morphine Ke0*.001/Morphine V1
39
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Morphine Uptake = Morphine in Lung*.693/Morphine Absorption Half Life
OUTFLOWS:
Morphine Cl l = Morphine X 1 *Morphine K10
Morphine X2(t) = Morphine X2(t - dt) + (- Morphine C12) * dt
INIT Morphine X2 = 0
OUTFLOWS:
Morphine C12 = Morphine X2*Morphine K21-Morphine X1 *Morphine K12
Morphine X3(t) = Morphine X3(t - dt) + (- Morphine Cl3) * dt
INIT Morphine X3 = 0
OUTFLOWS:
Morphine Cl3 =Morphine X3*Morphine K31-Morphine Xl*Morphine K13
Morphine Xeffect(t) = Morphine Xeffect(t - dt) + (- Morphine CLe) * dt
INIT Morphine Xeffect = 0
OUTFLOWS:
Morplxine CLe = Morphine Xeffect~°Morphine Ke0-
Morphine X1*Morphine Ke0*.001/Morphine V1
PaCO2(t) = PaC02(t - dt) + (CO2 Accumulation - C02Equilb) ~` dt
INIT PaC02 = PaCO2@0
INFLOWS:
CO2 Accumulation=Ke1C02*PaCO2@0-KelCO2*Ventilatory Depression*PaC02
OUTFLOWS:
C02Equilb = ke0C02*(PaC02-PeC02)
PeCO2(t) = PeC02(t - dt) + (C02Equilb) * dt
INIT PeC02 = PaC02@0
INFLOWS:
C02Equilb = ke0C02*(PaC02-PeC02)
Sedation State(t) = Sedation State(t - dt) + (Sedation Evaluator) * dt
INIT Sedation State = 0
INFLOWS:
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Sedation Evaluator = if Combined Opioid Effeci Site Concentration<Sedation
Threshold then
0 else 1
Alfentanil Absorption Half Life = 1
Alfentanil Ce = Alfentanil Xeffect/.001
Alfentanil Cp = Alfentanil X1/Alfentanil Vl
Alfentanil Dose ug = 1500
Alfentanil K10 = 0.090957
Alfentanil K12 = 0.655935
Alfentanil K13 = 0.112828
Alfentanil K21 = 0.214
Alfentanil K31 = 0.017
Alfentanil Ke0 = 0.77
Alfentanil V 1 = 2.18
C50 = 1.1
Combined Opioid Effeci Site Concentration = Alfentanil Ce/60+Morphine Ce/70
Dose Duration= 12
F=4
Gamma = 1.2
ke0C02 = 0.92
Ke1C02 = 0.082
Morphine Absorption Half Life = 2
Morphine Ce = Morphine Xeffect/.001
Morphine Cp=Morphine X1/Morphine Vl
Morphine Dose mg = 20
Morphine K10 = 0.070505618
Morphine K12 = 0.127340824
Morphine K13 = 0.018258427
Morphine K21 = 0.025964108
Morphine K31 = 0.001633166
Morphine Ke0 = 0.005
41
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
Morphine V 1 = 17.8
PaC02@0 = 40
Sedation Threshold = 1.5
Ventilatory_Depression = (1-
Combined Opioid Effeci Site Concentration^Gamma/(C50^Gamma+Combined Opioid
Effeci_
Site Concentration^Gamma))*(PeC02/PaC02@0)^F
The simulation was run with a starting parameter of 700 mcg of bioavailable
alfentanil and 67 mcg of bioavailable morphine in the inhaler at time 0
(Alfentanil In
Inhaler = 700 mcg at time = 0; Morphine In Inhaler = 67 mcg at time 0). Figure
18 and
19 shows the concentrations of various parameters when the simulation was run.
Figure
18 showed concentration of alfentanil (in ng/ml, line 1), morphine (in ng/ml,
line 2) and
combined opioid (in ng/ml of fentanyl equivalents, line 3) over time (in
minutes) at the
effect site following inhalation of the combined product. In this example,
drug
administration has terminated after 90% of the inhaled drug was delivered
because of
patient sedation. As can be seen, the alfentanil concentration rises quickly
in the effect
site (line 1) producing a rapid drug effect. The morphine drug effect rises
quite slowly in
the effect site (line 2), producing a slowly rising drug effect. Line 3 is
shows the
combined opioid effect site concentrations, where each drug has been adjusted
for its
potency relative to fentanyl. All three lines have different Y scales, as can
be seen on the
Y axis, to normalize the effect site concentrations for relative potency. As
can be seen in
line 3, the highest opioid exposure occurs at the time of inhalation, and is
almost entirely
due to the alfentanil. However, as the alfentanil washes out of the effect
site, it is almost
exactly replaced by the influx of morphine into the effect site. A
concentration at the site
of effect of less than 25 ng/ml on the alfentanil scale (equivalent to 37.5
ng/ml on the
morphine scale and 0.5 ng/ml on the fentanyl scale due to their relative
potency) is
considered sub-therapeutic; a patient will typically feel analgesic effects
between 50
ng/ml and 100 ng/ml (on the alfentanil scale), side effects between 75 and 125
ng/ml (on
the alfentanil scale) and toxic effects above 125 ng/ml (on the alfentanil
scale).
Figure 19 showed the ventilatory depression from the inhalation of an
alfentanil
morphine combination opioid delivery system. As shown in figure 19, the
ventilation
decreases to about 65% of baseline during drug administration, and then
recovers to
42
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
approximately 80% of baseline as C02 accumulates. Ventilation is maintained at
80% of
baseline throughout the next 4 hours, as the morphine effect is sustained.
As demonstrated in figures 17, 18, and 19, in the alfentanil morphine
combination
opioid delivery system, based on simulations using parameter values taken from
the
literature, the patient self limiting opioid delivery system prevents
administration of a
toxic dose of opioid, and provides for the safe delivery of a slowly acting
opioid by
combining the slowly acting opioid with a rapidly acting opioid, and using the
effects of
the rapidly acting opioid to limit the total opioid exposure.
Example 5: Clinical testing of Fentanyl preparations in human subiects
(a) Metlaod of Preparation of Free and Liposome Encapsulated Fentarayl
Preparations
Preparations containing a mixture of free fentanyl and liposome encapsulated
fentanyl were prepared by mixing an ethanolic phase with an aqueous phase. The
ethanolic phase comprised ethanol, fentanyl citrate, phosphatidylcholine and
cholesterol.
The aqueous phase comprised water for injection. Before mixing, both phases
were
heated to a temperature of about 56 to 60 degrees centigrade. The two phases
were mixed
and the mixture was stirred for a further 10 minutes at 56-60 degrees
centigrade. The
mixture was then allowed to cool to room temperature over approximately two
hours.
Typically, each ml of the final aqueous formulation contained 500 mcg
fentanyl, 40 mg
phosphatidylcholine, 4 mg cholesterol, and 100 mg ethanol. After filling,
preparations
were autoclaved for final sterilization. Final preparations contained between
35 to 45%
of the fentanyl as free drug with the remainder in the encapsulated fraction.
Lb) Treatment protocol
The procedure of the following example shows how the administration of a
mixture of free and liposome encapsulated fentanyl through the lungs of a
patient delivers
therapeutically effective concentrations to the bloodstream and that side
effects of
hypoxia are generally (but not always) preceded by somnolence, dizziness or
sedation
during the administration period.
Healthy volunteer subjects were treated with single or multiple doses of a
mixture
of free and liposome encapsulated fentanyl using the AeroEclipseTM Nebulizer
breath-
actuated unit with compressed air set at 8 litres/minute. During each dosing
period the
nebulizer was charged with a 3 ml of the mixture of free (40%) and liposome
43
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
encapsulated (60%) fentanyl and the subjects were instructed to inhale
nebulized drug
until the device no longer generated aerosol for inhalation. Subjects that
become drowsy,
sleepy or dizzy during the inhalation period were encouraged to continue to
self
administer the drug until the nebulizer was no longer generated aerosol.
Plasma samples
were collected through the administration period and for the 12 hours
following initiation
of administration to monitor plasma fentanyl concentrations. Patients were
monitored for
any adverse events, including changes in respiratory rate and hypoxia.
Control subjects were given intravenous fentanyl.
(c) Measurement of maximum plasma concentration arad erad of dose plasma
concentration
In order to determine whether patients could prevent toxic levels of drug by
self
limiting the drug before a toxic effect was exhibited, maximum plasma
concentration
(Cmax) was plotted against plasma concentration at end of dosing (Ceod)
(Figure 20A).
Ceod was found in most cases to be within 80% of Cmax, indicating that the
maximum
concentration of opioid was not significantly higher than the concentration at
the time the
subject stopped taking the opioid. This is in stark contrast to the control
subjects (Figure
20B) where patients given intravenous fentanyl exhibited Cmax concentrations
significantly higher than Ceod. This indicates an increased safety in
titration of drug by
the subjects, since the concentration (and resulting toxic effects) of the
opioid will not
increase significantly after the subject stops taking the opioid. This
indicates that, in an
inhaled opioid formulation of the disclosed concentration over a relatively
long period of
time (2-20 minutes), if the "end of dose" amount is non-toxic, the maximum
concentration of opioid taken by the subject is likely also non-toxic.
(d) Detef°miraation of tinge points for side effects and toxic effects
In order for subjects to effectively self titrate, side effects of the drug
such as
drowsiness, dizziness or ventilatory depression should occur before the onset
of toxic
effects. Toxic effects were defined in this experiment as blood hypoxia
resulting in a
blood oxygen saturation lower than 90% of normal for the subject. In order to
determine
whether side effects occur before toxic effects, time to a side effect, and
time to a toxic
effect, were plotted against time to end of dose (Figure 21). For any end of
dose time,
time to side effect was equal or shorter than time to toxic effect, indicating
that
44
CA 02556629 2006-08-15
WO 2004/075879 PCT/CA2004/000303
drowsiness, dizziness or ventilatory depression always took place before or at
the time of
toxic effect.
(e) Determination of correlation between toxic effect and side effect
In order for subjects to effectively self titrate, a toxic effect should be
almost
always preceded by a side effect causing (or signaling) the cessation of
administration of
drug. Figure 22 shows, for the total population of the study, that side effect
is closely
correlated to toxic effect, indicating that it is extremely likely that a subj
ect exhibiting a
toxic effect will have also exhibited a side effect.
This example shows, in a controlled trial of human subjects, that (1) a toxic
effect
is almost always preceded by a side effect, and that (2) Cmax of inhaled
opioid, in the
dose profile given in this example, is approximately Ceod. Therefore, a
subject who
stops administration of opioid when a side effect is felt will likely not
reach opioid
concentration levels required for toxic effect.
